OnDemand

In this informative session, Jennifer Sharpe, Executive Director, Gross-to-Net at IntegriChain is joined by Meera Phaltankar, Director of Revenue Accounting at Ironshore Pharmaceuticals in a discussion surrounding pressing issues for business and financial professionals in the life sciences industry. They examine challenges, ways to mitigate risk, and industry best practices that will increase GTN confidence and accuracy for pharmaceutical manufacturers. Topics include:

• Understanding the structure and levers of patient funnel models to successfully forecast Coverage Gap and co-pay liabilities
• Successful practices to mitigate the inherent risks of 340B management including double-dip, entity eligibility, and utilization diversion
• Achieving audit support gold standard by utilizing analog data from returns, 340B, Medicaid, and other GTN lines
• Leveraging Medicaid Claim Level Detail to analyze Medicaid invoice lag time and accrual development
• Implementing a platform-centric approach to successful GTN management initiatives that drive optimization and timely insights 

Interested in learning more about how IntegriChain helps pharma manufacturers optimize gross-to-net? Using data-driven models, we help companies achieve a confident forecast and clear view of a drug’s true net price.

LEARN MORE ABOUT GTN

Jennifer Sharpe
Executive Director, Gross-to-Net

Meera Phaltankar
Director, Revenue Accounting
Ironshore Pharmaceuticals Inc.

Learn more about how manufacturers can leverage successful returns and inventory pipeline reserve methodologies for long-term benefits.